Emotional and cognitive disturbances in long-term melanoma survivors treated with ipilimumab.

97Background: Immunotherapy with the CTLA-4 blocking mAb ipilimumab (IPI) has improved the long-term (>3 y) survival of a subpopulation (15-20%) of patients (pts) with metastatic melanoma. Little i...